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A Rose by Any Other Name:
A Valve by Any Other Method
The interest in catheter-based treatment of aortic stenosis is at a fever pitch, as indicated by
the standing-room crowds packing the presentations at the recent ACC Scientific Sessions in
Chicago. We, at JACC: Cardiovascular Interventions, have also been overwhelmed by the large
number of submissions on the subject. There are so many important papers that we decided to
dedicate this issue exclusively to transcatheter aortic valve intervention (TAVI). Is that
excitement driven by the dramatic results of the PARTNER (Placement of AoRTic
TraNscathetER Valve) trials or by the worldwide adoption of this technology outside the
United States? My view is that the main driver of the current interest in the United States is
the pending Center for Medicare and Medicaid Services (CMS) action which will approve
reimbursement for TAVI (or is it TAVR?). But what is in a name? Maybe not much, but an
interesting linguistic divide has emerged in naming the procedure. You will notice that TAVI,
the original designation, has morphed into “TAVR” in the United States but remains TAVI in
the world where it is already approved. Is that because authors from outside North America
need a native English speaker to edit their manuscripts? Hardly, since in England it remains
“TAVI”, and on last check, English is widely spoken there. Is the change because the valve is
“replaced” rather than simply “implanted”? Certainly not. Perhaps one could make the point
that the valve function is being replaced, although in common parlance, “replaced” indicates
that something is removed and another is put in its place. “Placed” would work but who could
pronounce “TAVP”? Implantation seemed okay, and of note, most papers in this focused issue
used the designation “TAVI”. The selected papers for this issue reflect the dominance of the
international experience with this technique. So, why has the name been changed in the
United States? Is it because TAVR has a throaty, more macho sound than TAVI? Perhaps
not, but we are getting close. The role of CMS and other insurance carriers should be
considered. There are codes existing for aortic valve surgery which use the current language of
aortic valve replacement since the old valve is removed and a new one is put in. Perhaps the
more “macho” name can engender a more robust reimbursement. Do not get me wrong—I
have been involved with a few percutaneous and minimally invasive transcatheter valve
procedures and they are demanding and technically complex and deserve reimbursement that is
appropriate. Ahhh, but what is in a name?
Perhaps I should move to a more serious topic concerning this potentially revolutionary
technology. As the CMS approval is pending, the question of who will be performing the
procedures is of great interest. The CMS will mandate institutional and operator experience or
at least the performance of other structural heart disease procedures that can make the
mastering of these procedures likely. What kind of experience will serve as qualification to
become an aortic valve implanter? Is a high volume of percutaneous coronary interventions
(PCIs) helpful? Is “structural heart” experience helpful if it is predominantly closure of patent
foramen ovale? Cardiothoracic surgery will play a prominent gatekeeper role since approval for
reimbursement will be only for those patients judged to be at prohibitive operative risk by
2 surgeons. How many hospitals will be launching this activity? There is speculation that 200 to
400 sites may be approved. If PCI is any indicator, there will be enormous political pressure to
expand the number of sites with the argument for enhanced patient access. Until and unless this
technology becomes completely user-friendly, restriction to centers that can provide high volumes of
procedure.
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596experience seems a more rational approach. There is no
doubt that there is a learning curve, but the impact on
patients should be held to a minimum even if it slows the
proliferation of the procedure.
Another issue that will not be resolved in the short
term is who should have the procedure. Current approval
is for extremely high-risk patients who are not only
Medicare recipients (ergo: the importance of CMS in this
discussion) but on average are over 80 years of age, and
many over 90 years of age. Although the PARTNER results
dramatically favored the treatment group, mortality from
other causes remains high in this population. Identification
of which patients are likely to have a sustained benefit and
which ones are not is an important area for investigation.
The ethical debate about distributive justice related to
technologies that consume large amounts of healthcare
resources will be intensifying in years to come.
Although approval will be for inoperable patients, the
PARTNER cohort A trial 2-year results reported at the
ACC Scientific Session continued to show parity with
surgical approaches in high-risk but operable patients, and
the PARTNERS II trial of intermediate-risk patients andthe CoreValve trials are under way. These necessary,
randomized, controlled trials, emanating largely from the
United States, and vast observations from countries with
approval, will likely lead to widespread use of these
technologies and those that grow from this innovation. It
was a wise decision for the sponsors and the Food and
Drug Administration to insist on a collegial involvement
of surgeons and cardiologists. Hopefully, for the sake of
patients, the “heart team” will survive after wider
dissemination of the method.
This year in Rouen, France, many pioneers celebrated
with Alain Cribier the 10th anniversary of TAVI.
Whether we call this “rose” TAVI or TAVR, for the
patients who will benefit, it is truly “sweet”!
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